Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: vitamin D analogues - Aphios

Next Previous
X
Search
Drug Profile

Research programme: vitamin D analogues - Aphios

Alternative Names: 1,25(OH)2D3-3-BE; AMPI-109; APH-0701; APH-1201; APH-M109; MPI-105; MPI-106; MPI-107

Latest Information Update: 25 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boston University School of Medicine
  • Developer Aphios Corporation
  • Class Antineoplastics; Dihydroxycholecalciferols
  • Mechanism of Action Apoptosis stimulants; Calcitriol stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 25 Nov 2021 APH 0701 is still in preclinical development for prostate cancer (hormone refractory) in USA (IV) (Aphios Corporation pipeline, November 2021)
  • 13 Nov 2019 Aphios has patent protection for vitamin D3 analog nanoparticles in the US
  • 20 Oct 2014 Active development in Prostate cancer (hormone refractory) (IV) is ongoing in the US

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top